HIMS

HIMS

USD

Hims & Hers Health Inc. Class A Common Stock

$44.070-1.680 (-3.672%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$45.750

最高

$48.340

最低

$43.620

交易量

36.16M

公司基本面

市值

10.0B

行業

Drug Manufacturers - Specialty & Generic

國家

United States

交易統計

平均交易量

28.91M

交易所

NYQ

貨幣

USD

52週範圍

最低 $19.15當前 $44.070最高 $72.98

相關新聞

Analyst Upgrades

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32

B of A Securities analyst Allen Lutz maintains Hims & Hers Health with a Underperform and raises the price target from $28 to $32.

查看更多
B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32
Reuters

Futures tumble after Wall St banks warn of market pullback, Palantir slides

U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.

查看更多
Futures tumble after Wall St banks warn of market pullback, Palantir slides
Analyst Upgrades

BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target

BTIG analyst David Larsen reiterates Hims & Hers Health with a Buy and maintains $85 price target.

查看更多
BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target
Reuters

Hims and Hers beats revenue estimates on strong subscriber growth

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings.

查看更多
Hims and Hers beats revenue estimates on strong subscriber growth
BusinessWire

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3

查看更多
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
PR Newswire

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.

A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray...

Analyst Upgrades

Keybanc Initiates Coverage On Hims & Hers Health with Sector Weight Rating

Keybanc analyst Justin Patterson initiates coverage on Hims & Hers Health with a Sector Weight rating.